Sarepta Therapeutics Inc (SRPT) Given Average Rating of “Buy” by Brokerages
Sarepta Therapeutics Inc (NASDAQ:SRPT) has been given a consensus recommendation of “Buy” by the twenty-four analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and sixteen have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $65.27.
SRPT has been the subject of several recent analyst reports. Oppenheimer restated a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 16th. Barclays initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $46.00 target price for the company. Morgan Stanley upgraded shares of Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and set a $60.00 target price for the company in a research note on Monday, October 2nd. Robert W. Baird reiterated an “outperform” rating and issued a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Finally, Credit Suisse Group raised their price objective on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the company an “outperform” rating in a research note on Thursday, September 7th.
Sarepta Therapeutics (SRPT) traded down $0.44 during mid-day trading on Thursday, hitting $53.65. 1,153,164 shares of the stock traded hands, compared to its average volume of 1,750,000. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $57.57. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.
In other Sarepta Therapeutics news, CEO Douglas S. Ingram bought 38,138 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was purchased at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the acquisition, the chief executive officer now owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the transaction, the director now owns 13,333 shares of the company’s stock, valued at $745,181.37. The disclosure for this sale can be found here. Insiders have sold a total of 28,167 shares of company stock valued at $1,497,619 over the last 90 days. 9.60% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the business. Alliancebernstein L.P. increased its holdings in Sarepta Therapeutics by 63.3% during the 2nd quarter. Alliancebernstein L.P. now owns 118,310 shares of the biotechnology company’s stock valued at $3,988,000 after acquiring an additional 45,860 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth about $630,000. Eagle Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 33.4% during the second quarter. Eagle Asset Management Inc. now owns 798,412 shares of the biotechnology company’s stock worth $26,914,000 after buying an additional 200,103 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Sarepta Therapeutics by 96.4% during the second quarter. Russell Investments Group Ltd. now owns 75,170 shares of the biotechnology company’s stock worth $2,534,000 after buying an additional 36,897 shares in the last quarter. Finally, 361 Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $1,914,000. Hedge funds and other institutional investors own 82.02% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/14/sarepta-therapeutics-inc-srpt-given-average-rating-of-buy-by-brokerages.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.